Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities researchers at FBR & Co issued their FY2017 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a report released on Monday. FBR & Co analyst M. Kumar forecasts that the biopharmaceutical company will post earnings of ($4.60) per share for the year. FBR & Co currently has a “Buy” rating and a $150.00 target price on the stock. FBR & Co also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.09) EPS, Q2 2018 earnings at ($1.64) EPS, Q3 2018 earnings at ($0.69) EPS, Q4 2018 earnings at ($0.14) EPS, FY2018 earnings at ($3.55) EPS, FY2019 earnings at ($0.28) EPS, FY2020 earnings at $3.63 EPS and FY2021 earnings at $6.35 EPS.
Several other research firms have also recently weighed in on ALNY. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 target price (down from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. Zacks Investment Research raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $88.00 target price for the company in a research note on Wednesday, July 12th. BMO Capital Markets reaffirmed an “outperform” rating and set a $99.00 target price (down from $105.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 6th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $110.00 target price (down from $126.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. Finally, Instinet began coverage on shares of Alnylam Pharmaceuticals in a research note on Friday, September 15th. They set a “reduce” rating and a $56.00 target price for the company. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $105.11.
COPYRIGHT VIOLATION NOTICE: “Research Analysts Issue Forecasts for Alnylam Pharmaceuticals, Inc.’s FY2017 Earnings (ALNY)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.com-unik.info/2017/11/01/research-analysts-issue-forecasts-for-alnylam-pharmaceuticals-inc-s-fy2017-earnings-alny.html.
Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded up 0.50% during mid-day trading on Wednesday, reaching $122.45. The company had a trading volume of 66,235 shares. The stock has a 50 day moving average of $111.79 and a 200-day moving average of $83.47. Alnylam Pharmaceuticals has a one year low of $31.38 and a one year high of $126.16. The firm’s market capitalization is $11.23 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). The business had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business’s quarterly revenue was up 82.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.05) EPS.
In other news, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the sale, the president now owns 165,399 shares in the company, valued at approximately $16,539,900. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Barry E. Greene sold 85,316 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $125.00, for a total transaction of $10,664,500.00. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in ALNY. Parametric Portfolio Associates LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 71.2% in the 1st quarter. Parametric Portfolio Associates LLC now owns 60,030 shares of the biopharmaceutical company’s stock worth $3,077,000 after acquiring an additional 24,967 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Alnylam Pharmaceuticals by 11.9% in the 1st quarter. JPMorgan Chase & Co. now owns 62,986 shares of the biopharmaceutical company’s stock worth $3,228,000 after acquiring an additional 6,678 shares during the last quarter. Prudential Financial Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth about $215,000. Teachers Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 9.1% in the 1st quarter. Teachers Advisors LLC now owns 80,238 shares of the biopharmaceutical company’s stock worth $4,112,000 after acquiring an additional 6,662 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 0.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock worth $446,000 after acquiring an additional 36 shares during the last quarter. Hedge funds and other institutional investors own 94.39% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
What are top analysts saying about Alnylam Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alnylam Pharmaceuticals Inc. and related companies.